

*Not for distribution or release in the United States or to U.S. persons*

ASX Announcement

6 June 2024

## GENETIC SIGNATURES SUCCESSFULLY COMPLETES INSTITUTIONAL ENTITLEMENT OFFER AND PLACEMENT

Genetic Signatures Limited ACN 095 913 205 (GSS, Genetic Signatures or the Company) is pleased to announce the successful completion of the bookbuild for the institutional placement (**Placement**) and the institutional component (**Institutional Entitlement Offer**) of its 1 for 5.82 pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer** and, together with the Placement, the **Offer**) of new fully paid ordinary shares in Genetic Signatures (**New Shares**), details of which were announced to the ASX on Tuesday, 4 June 2024.

The Placement and Institutional Entitlement Offer closed on Wednesday, 5 June 2024 (together, the **Institutional Offer**).

The Institutional Offer will raise gross proceeds of approximately A\$21.5 million (before costs) at an offer price of A\$0.75 per New Share, consisting of approximately A\$6.0 million under the Placement and approximately A\$15.5 million under the Institutional Entitlement Offer. The Institutional Offer attracted strong demand from existing institutional shareholders of the Company, and also introduced several new institutional investors to the Genetic Signatures register.

Funds raised under the Offer will be applied towards supporting the US commercialisation of the Enteric Parasite product in the US, including new customer installations and establishment of manufacturing capability in the US. In addition, proceeds will be used to fund the next generation instrument development, new product development and general working capital.

*“We appreciate the strong support we have seen from both new and existing shareholders in this capital raise,” said Dr Nick Samaras, Non-Executive Chairman of Genetic Signatures. “The Company is at a pivotal time in its history to commercialise the Enteric Parasite test in the US which will greatly improve patient diagnosis and treatment outcomes. The development of our high-throughput, sample-to-answer instrument will progress and promises to be a game-changer for the high-volume user sites we will be targeting in the US market. The proceeds from this raise provides the Company with the balance sheet it requires to fully realise the potential of these exciting growth opportunities.”*

No shareholder approval is required in connection with the issue of New Shares under the Placement, as the Placement is within the Company’s available Listing Rule 7.1 capacity (as upsized by an ASX ‘super-size’ waiver).

New Shares subscribed for under the Institutional Offer are expected to be settled on Wednesday, 12 June 2024 and to be issued on Thursday, 13 June 2024. New Shares issued under the Institutional Offer will rank equally with existing fully paid ordinary shares in Genetic Signatures as at their date of issue.

As announced to ASX on Tuesday, 4 June 2024, the Offer will raise approximately A\$30 million, comprising the Institutional Offer of approximately A\$21.5 million (including the Placement and Institutional Entitlement Offer) and the retail component of the Entitlement Offer (**Retail Entitlement Offer**) of approximately A\$8.5 million. The Entitlement Offer is fully underwritten by Bell Potter Securities Limited and Taylor Collison Limited.

Genetic Signatures expects ASX to lift its trading halt and for Genetic Signatures' ordinary shares to recommence trading on ASX on an ex-entitlements basis from market open today.

### **Retail Entitlement Offer**

The Retail Entitlement Offer is expected to open at 9.00am on Wednesday, 12 June 2024 and close at 5.00pm (Sydney, Australia time) on Monday, 1 July 2024. The despatch of the retail entitlement offer booklet for the Retail Entitlement Offer (**Booklet**) with personalised entitlement and acceptance forms for eligible retail shareholders is scheduled to occur on Wednesday, 12 June 2024.

Eligible retail shareholders with a registered address in Australia or New Zealand will be able to subscribe for 1 New Share for every 5.82 existing ordinary shares held in Genetic Signatures as at 7.00pm (Sydney, Australia time) on the record date of Thursday, 6 June 2024, at the same offer price of A\$0.75 per New Share, being the same as the price paid per New Share by investors in the Institutional Offer.

The terms and conditions under which eligible retail shareholders may apply for New Shares under the Retail Entitlement Offer will be outlined in the Booklet. Copies of the Booklet will be available on the ASX website and our website at from Wednesday, 12 June 2024.

Eligible retail shareholders should confirm the actual number of New Shares issued to them before trading in such shares, and the sale by any eligible retail shareholder of New Shares prior to receiving their holding statement is at their own risk.

### **Offer Timetable**

<b>Event</b>	<b>Time (Sydney time) / Date</b>
Back-to-back trading halt	Friday, 31 May 2024
Offer announcement and Placement and Institutional Entitlement Offer opens	Tuesday, 4 June 2024
Announcement of results of Placement and Institutional Entitlement Offer	Thursday, 6 June 2024

Trading in Genetic Signatures shares resumes on an ex-entitlement basis	Thursday, 6 June 2024
Record Date for determining entitlement for the Entitlement Offer	7.00 pm AEST Thursday, 6 June 2024
Retail Offer Booklet made available and retail Entitlement Offer opens	Wednesday, 12 June 2024
Settlement of Placement and Institutional Entitlement Offer	Wednesday, 12 June 2024
Allotment of New Shares issued under the Placement and Institutional Entitlement Offer	Thursday, 13 June 2024
Normal trading of New Shares issued under the Placement and Institutional Entitlement Offer	Friday, 14 June 2024
Retail Entitlement Offer closing date	5.00pm AEST Monday, 1 July 2024
Settlement of Retail Entitlement Offer	Friday, 5 July 2024
Allotment of New Shares issued under the Retail Entitlement Offer	Monday, 8 July 2024
Normal trading of New Shares issued under the Retail Entitlement Offer	Tuesday, 9 July 2024

*Note: The timetable above is indicative only and may be subject to change. All times and dates refer to Sydney time. GSS reserves the right to amend any or all of these dates and times without notice, subject to the Corporations Act 2001 (Cth), the ASX Listing Rules and other applicable laws. In particular, GSS reserves the right to extend the closing date of the Retail Entitlement Offer, to accept late applications under the Retail Entitlement Offer (either generally or in particular cases) and to withdraw the Entitlement Offer without prior notice. Any extension of the closing date will have a consequential effect on the issue date of New Shares under the Retail Entitlement Offer.*

– ENDS –

## Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr Neil Gunn**  
**Director and**  
**Interim Chief Executive Officer**  
[neil.gunn@geneticsignatures.com](mailto:neil.gunn@geneticsignatures.com)  
 T: +61 (0)2 9870 7580

**Karl Pechmann**  
**Chief Financial and Operating Officer**  
**and Company Secretary**  
[karl.pechmann@geneticsignatures.com](mailto:karl.pechmann@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.

### **Not an offer in the United States**

This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any jurisdiction in which such an offer would be illegal. The New Shares to be offered and sold in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933 (the **US Securities Act**) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States unless they are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

### **Forward looking statements**

This announcement contains certain "forward-looking statements" including but not limited to projections, that are based on management's beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions. Such forward-looking statements include statements regarding the timetable, conduct and outcome of the Offer and the use of proceeds thereof, statements about the plans, objectives and strategies of the management of Genetic Signatures, statements about the industry and the markets in which Genetic Signatures operates and statements about the future performance of the Genetic Signatures businesses. Indications of, and guidance or outlook on, future earnings or financial position or performance, future earnings and distributions are also forward-looking statements.

Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance, and estimates. The forward-looking statements contained in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Genetic Signatures and its subsidiaries, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. No representation, warranty, or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Genetic Signatures or any of its advisers).